DelveInsight’s, “Basal Cell Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Basal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Basal Cell Carcinoma Research. Learn more about our innovative pipeline today! @ Basal Cell Carcinoma Pipeline Outlook
Key Takeaways from the Basal Cell Carcinoma Pipeline Report
July 2024:- Sol-Gel Technologies, Ltd.- A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Gorlin Syndrome. The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use.
June 2024:- Biofrontera Bioscience GmbH- The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) with the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for superficial basal cell carcinoma (BCC).
DelveInsight’s Basal Cell Carcinoma Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Basal Cell Carcinoma treatment.
The leading Basal Cell Carcinoma Companies such as PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.
Promising Basal Cell Carcinoma Therapies such as BO-112, SP-002, Vismodegib, Nivolumab, Ipilimumab, Relatlimab, Vismodegib, and others.
Stay informed about the cutting-edge advancements in Basal Cell Carcinoma treatments. Download for updates and be a part of the revolution in cancer care @ Basal Cell Carcinoma Clinical Trials Assessment
Basal Cell Carcinoma Emerging Drugs
Patidegib: PellePharm
Patidegib is an investigational small molecule that inhibits hedgehog signaling. It is a topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently evaluated in Phase III clinical trials for the treatment of BCCs.
AIV001: AiViva BioPharma
AIV001 is a novel formulation of a multi-kinase inhibitor combined with AiViva’s proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers. AIV001 is in Phase I/II clinical studies for the treatment of patients with Basal Cell Carcinoma.
Learn more about Basal Cell Carcinoma Drugs Opportunities in our groundbreaking Basal Cell Carcinoma Research and development projects @ Basal Cell Carcinoma Unmet Needs
Basal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Type
Basal Cell Carcinoma Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Discover the latest advancements in Basal Cell Carcinoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Basal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives
Scope of the Basal Cell Carcinoma Pipeline Report
Coverage- Global
Basal Cell Carcinoma Companies- PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others.
Basal Cell Carcinoma Therapies- BO-112, SP-002, Vismodegib, Nivolumab, Ipilimumab, Relatlimab, Vismodegib, and others.
Basal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Basal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Basal Cell Carcinoma Pipeline on our website @ Basal Cell Carcinoma Emerging Drugs and Companies
Table of Content
Introduction
Executive Summary
Basal Cell Carcinoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Basal Cell Carcinoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Patidegib: PellePharm
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
IO103: IO Biotech
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
AIV001: AiViva BioPharma
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Cannabidiol: Leaf Vertical
Drug profiles in the detailed report…..
Inactive Products
Basal Cell Carcinoma Key Companies
Basal Cell Carcinoma Key Products
Basal Cell Carcinoma- Unmet Needs
Basal Cell Carcinoma- Market Drivers and Barriers
Basal Cell Carcinoma- Future Perspectives and Conclusion
Basal Cell Carcinoma Analyst Views
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
